Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

NCT04925193 | Active Not Recruiting Phase 2 Results DMC FDA Drug

• 2 other identifiers: 20-2202.ccP30CA046934
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to evaluate the outcomes achieved with selinexor based combination in RRMM selected by physician's choice and compared prospectively to ex vivo drug sensitivity testing results. Participants will be enrolled and assigned into one of three treatment selection groups. The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually. Selection groups are as follows: Group 1: Selinexor + pomalidomide + dexamethasone (SPd) Group 2: Selinexor + daratumumab + dexamethasone (SDd) Group 3: Selinexor + carfilzomib + dexamethasone (SKd)

Conditions

Multiple Myeloma in Relapse

Outcome Measures

Primary Outcomes (1)

• Overall Response Rate

  To evaluate the overall response rate achieved with physician's choice selinexor-based combination therapy as measured by International Myeloma Working Group criteria (based on Kumar et al 2016).

  End of Therapy, on average 10 months

Secondary Outcomes (5)

• MRD Negative Response Rate

  2 years following End of Treatment or date of progression (whichever comes first), assessed up to 2 years

• Progression Free Survival

  End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years

• Overall Survival

  EOT + 2 years, or date of progression (whichever comes first)

• Duration of Response

  End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years

• Time to Next Treatment

  End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years

Study Arms (1)

Arm 1

EXPERIMENTAL

Treatment Options: Selinexor 60 mg PO days 1, 8, 15 Pomalidomide 4 mg PO on days 1-21 Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22 28 day treatment cycles Selinexor 80 mg PO days 1, 8, 15 Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles \>6 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 28 day treatment cycle Selinexor 80 mg PO days 1, 8, 15 Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15. Dexamethasone 40 mg IV or PO days 1, 8, 15, 22 28 day treatment cycle

Drug: Selinexor; Drug: Pomalidomide; Drug: Daratumumab; Drug: Carfilzomib; Drug: Dexamethasone

Interventions

Selinexor DRUG

Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).

Arm 1

Pomalidomide DRUG

Oral Table

Arm 1

Daratumumab DRUG

Injection

Arm 1

Carfilzomib DRUG

Injection

Arm 1

Dexamethasone DRUG

Oral tablet or injection

Arm 1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years
• Willing and able to provide written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
• Histologically confirmed diagnosis, measurable disease and evidence of disease progression of MM after 1 or more prior lines of therapy with either of:
• Documented evidence of PD after achieving at least SD for ≥ 1 cycle during a previous MM regimen (i.e., relapsed MM)
• ≤ 25% response (i.e, patient never achieved ≥ MR) or PD during or within 60 days from end of the most recent MM regimen (i.e., refractory MM)
• Patients must have measurable disease as defined by at least one of the following:
• a) Serum M-protein ≥ 0.5 g/dL by serum protein electrophoresis (SPEP) or, for IgA myeloma, by quantitative IgA c) Urinary M-protein excretion at least 200 mg/24 hours d) Serum FLC ≥ 10 mg/dL, provided that FLC ratio is abnormal e) If no measurable disease by serum or urine, then the presence of a plasmacytoma of ≥ 2cm in one dimension prior to start of study can be used to follow response via radiologic imaging
• Adequate hepatic function:
• f) Total bilirubin \<1.5 × upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \<3 × ULN), and g) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<2.5 × ULN.
• Adequate renal function as determined by serum creatinine of ≤ 2 mg/dL OR estimated creatinine clearance of ≥ 20 mL/min, calculated using the Cockcroft and Gault formula (140 - Age) • Mass (kg)/ (72 • creatinine mg/dL); multiply by 0.85 if female.
• Adequate hematopoietic function within 28 days prior to C1D1: absolute neutrophil count ≥1000/mm3, hemoglobin ≥8 g/dL and platelet count ≥100,000/mm3 (patients for whom \<50% of bone marrow nucleated cells are plasma cells) or ≥50,000/mm3 (patients for whom ≥50% of bone marrow nucleated cells are plasma cells).
• Patients may receive hematopoietic growth factor support, including erythropoietin, darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and platelet stimulators (eg, eltrombopag, romiplostim, or interleukin-11) at any time
• Patients may receive RBC and/or platelet transfusions as clinically indicated per institutional guidelines during the study.
• Female patients of childbearing potential must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 3 months following the last dose of protocol required therapies.

You may not qualify if:

• Has received selinexor or another XPO1 inhibitor in a previous line of therapy
• Has any concurrent medical condition or disease (eg, uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.) that is likely to interfere with study procedures.
• Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.
• Known intolerance, hypersensitivity, or contraindication to glucocorticoids.
• Pregnant or breastfeeding females.
• Major surgery within 4 weeks prior to C1D1.
• Active, unstable cardiovascular function, as indicated by the presence of:
• Symptomatic ischemia, or
• Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or
• Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction \<40%, or
• Myocardial infarction within 3 months prior to C1D1.
• Subjects with active hepatitis B virus (Hep B) are allowed if antiviral therapy for hepatitis B has been given for \>8 weeks and viral load is \<100 IU/ml prior to first dose of trial treatment. Subjects with untreated hepatitis C virus (HCV) are allowed.
• Subjects with Human Immunodeficiency Virus (HIV) who have CD4+ T-cell counts ≥ 350 cells/µL and no history of AIDS- defining opportunistic infections in the last year are allowed.
• Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment, including prior gastric bypass or bowel resection procedures.
• Inability or unwillingness to take supportive medications such as anti-nausea and anti anorexia agents as recommended by the NCCN CPGO for antiemesis and anorexia/cachexia (palliative care).

Sponsors & Collaborators

• University of Colorado, Denver: lead
• Karyopharm Therapeutics Inc: collaborator
• National Cancer Institute (NCI): collaborator

Study Sites (1)

University of Colorado Hospital

Aurora, Colorado, 80045, United States

Location

MeSH Terms

Interventions

selinexor; pomalidomide; daratumumab; carfilzomib; Dexamethasone

Intervention Hierarchy (Ancestors)

Pregnadienetriols; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Fluorinated

Results Point of Contact

• Title: Daniel Sherbenou
• Organization: HCTU

DANIEL.SHERBENOU@cuanschutz.edu

(303) 724-9520

Study Officials

• Daniel Sherbenou, MD

  University of Colorado, Denver

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually.

Study Record Dates

• First Submitted: May 19, 2021
• First Posted: June 14, 2021
• Study Start: November 18, 2021
• Primary Completion: August 6, 2024
• Study Completion (Estimated): November 1, 2026
• Last Updated: March 6, 2026
• Results First Posted: March 6, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)